Mild Behavioral Impairment an Early Indicator of Alzheimer’s

Based in Atlanta, Eugene E. Houchins III is the founder and president of the American Life Fund Corp, a company that offers pathways to funds for people with life-threatening conditions. Eugene E. Houchins III is particularly interested in cancer research and Alzheimer’s disease research.

According to recent research conducted at the McGill University Research Centre for Studies in Aging, a correlation exists between mild behavioral impairment (MBI) and Alzheimer’s disease. The noncognitive symptoms of MBI typically occur among individuals who are still cognitively healthy.

The study found that MBI is strongly associated with amyloid plaques in the brain, which is an initial pathological change associated with the early stages of Alzheimer’s. These specific proteins are associated with abnormal human behavior such as MBI, which can subsequently manifest as memory loss.

By using an MBI checklist, physicians may be able to identify people who are at a higher risk of dementia even before symptoms begin to manifest. The result will be treatment at earlier stages of Alzheimer’s progression, which may have a greater chance of slowing or reversing the disease.

Promising Results for New Alzheimer’s Treatments

Well-versed in insurance, entrepreneur Eugene E. Houchins III serves as president and CEO of American Life Fund Corp. With his company, Eugene E. Houchins III helps patients who are suffering from serious illnesses to access funds from their life insurance policies, helping them cover living and medical expenses. Aside from his professional duties, he is a supporter of philanthropic organizations contributing to research on diseases like cancer and Alzheimer’s disease.

Alzheimer’s disease is a progressive brain disorder that causes individuals to lose thinking skills, memory, and eventually the ability to perform simple tasks. There is currently no cure for Alzheimer’s disease, and it is irreversible once it begins to progress.

Because of the complexity of Alzheimer’s disease, doctors tend to treat Alzheimer’s by focusing on slowing down the progression and symptoms, managing any behavioral symptoms, and helping to maintain mental function as much as possible. There are several prescription drugs available that can help manage symptoms in the early to middle stages of the disease. As the disease progresses, some people find drugs called cholinesterase inhibitors effective in reducing symptoms and controlling behavioral issues that can arise.

Alzheimer’s disease is thought to be caused in part by a buildup of a particular protein known as beta-amyloid in the brain. In 2019, researchers at the University of Southern California in Los Angeles began exploring a new compound called 3K3A-APC, a modified activated C protein. Activated C protein protects the blood vessels and brain cells from damage caused by inflammation. This new compound, 3K3A-APC, has shown promise in trials for other brain diseases, so researchers decided to try this with Alzheimer’s disease as well. More research is likely on the horizon to see how effective this treatment may be.

New Treatment Could Increase Survival Rates after Chemotherapy

Through his firm American Life Fund Corp., Eugene E. Houchins III helps his clients gain access to funds needed for things such as uninsured medical costs. Eugene E. Houchins III takes a professional interest in innovations that could improve the survival rate of cancer patients.

Persons with lymphoma and leukemia may one day benefit from new research that suggests using existing drugs to fight cancer in a new and potentially much more effective way can increase survival rates.

No method now exists for curing or removing these cancers. Patients often receive chemotherapy with the goal of killing all cancer cells, staving off the disease. Unfortunately, cancer cells often develop resistance to chemo during treatment, and the tumors are not eradicated.

Researchers are now looking at a class of drugs known as small molecule inhibitors that takes advantage of cancer cells’ need for healthy adjacent cells (called stroma cells) to survive. Isolating the stroma cells from the tumor robs it of necessary nutrients and the cancer cells die.

Until now, scientists have not known how to accomplish this, but a recent study demonstrates that proteins known as PKC-inhibitors can starve tumor cells by affecting the stromas. Previous researchers who attempted to strike cancer cells directly with PKC saw poor results.

Treating both tumor and stroma cells improved survival rates considerably – in one case extending the period by 90 percent when compared to targeting tumors only. It had the added benefit of fighting several types of leukemia and lymphoma.

If other researchers can replicate these results, the outlook for patients with lymphoma and leukemia will be brighter.

Applying for a Viatical Settlement with ALF

Holding a master’s degree in environmental engineering from the Georgia Institute of Technology, Eugene E. Houchins III is the president and founder of the American Life Fund (ALF) corporation, a business that offers viatical settlement services for individuals with life-threatening illnesses such as cancer. Eugene E. Houchins III is dedicated to turning ALF into a leader in the field.

A viatical settlement is an agreement between the insured of an existing life insurance policy and a third-party company. The agreement consists of the purchase of the life insurance policy of the insured person for an immediate cash payout inferior to the death benefit, but higher than the cash surrender value. The third-party company then becomes the new life insurance policyholder, while the insured receives the lump sum cash payout.

To apply for a viatical settlement with ALF, the insured person can start by estimating the value of his or her policy, which will vary depending on the age, gender, type and stage of illness, and value of life insurance plan. Then, the applicant can download the application forms, fill them out, and send them to the company via email, FedEx, mail or fax.

After the forms are received, the applicant will speak with a financial counselor who will explain more about how the process of a viatical settlement works. Depending on the policyholder’s resident location, they may be referred to a licensed person or entity in that particular state. ALF always recommends that the insured contact both his or her legal and accounting representative prior to entering into this type of transaction and discussing alternatives with a licensed life insurance agent or life settlement broker.